Proceedings of the International scientific and practical conference ―New York Global Science Conference 2026‖ (March 6-8, 2026) / Publisher website: www.naukainfo.com. – New York, USA, 2026. - 250 p.

199 MEDICAL SCIENCES AND PUBLIC HEALTH UDC 616.36-003.826-008.9-092-078: 577.112.823 Natalia Zhelezniakova doctor of medicine, professor Tetiana Aleksandrova PhD, associate professor Volodymyr Molodan candidate of medical science, associate professor Kharkiv National Medical University Kharkiv, Ukraine HISTONE ALTERATION AS EPIGENETIC DETERMINANTS OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE PATHOGENESIS Abstract . Metabolic dysfunction-associated steatotic liver disease (MASLD) occupies a prominent position in hepatology and is increasingly recognized as a global epidemic. Accumulating evidence indicates that MASLD represents the hepatic manifestation of a systemic metabolic disorder. The pathogenesis of metabolic diseases is complex and multifactorial, involving the interplay of genetic and epigenetic determinants. Although genetic susceptibility plays a well-established role in MASLD pathogenesis, the rapidly increasing prevalence of the disease cannot be adequately explained by genetic predisposition and environmental exposures alone. Epigenetic regulation, encompassing reversible and heritable modifications of gene expression without changes in the underlying nucleotide sequence, constitutes a